Annual sunscreen expenses fluctuated between $40 and $1400 based on product pricing and concurrent sun-protective behaviors.
Patients with chronic back pain reported heightened unpleasantness of auditory stimuli and mechanical pressure.
The FDA accepted a New Drug Application with Priority Review for brepocitinib, an oral TYK2/JAK1 inhibitor, for the treatment of dermatomyositis.
Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.
Obinutuzumab was superior to placebo for systemic lupus erythematosus in a phase 3 trial, significantly improving SRI-4 response rates.
The table below is a review of notable updates that occurred in February 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
Early sport specialization was associated with more hip or groin pain, surgical treatment of the hip, and quitting the sport due to injury. HealthDay News — Repetitive stress from early single-sport ...
Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results